Clinical Trial24 Jan 2026, 05:11 pm
Hester Biosciences Receives Manufacturing License for Inactivated Avian Influenza Vaccine
AI Summary
Hester Biosciences Limited has received a manufacturing license from the Food & Drugs Control Administration to produce and market the Low Pathogenic Avian Influenza Vaccine, Inactivated H9N2 strain for poultry. This strain has been a persistent challenge in poultry flocks, leading to significant economic losses. The vaccine, developed from technology acquired from ICAR-NIHSAD via Agrinnovate India, is a key regulatory milestone in advancing Hester’s prevention-led poultry healthcare portfolio.
Key Highlights
- Hester Biosciences receives manufacturing license for Inactivated Avian Influenza Vaccine for poultry
- The vaccine is designed to combat the Low Pathogenic Avian Influenza H9N2 strain, a persistent challenge in poultry flocks
- The vaccine has the potential to prevent significant economic losses in the poultry industry
- The license is a key regulatory milestone for Hester’s prevention-led poultry healthcare portfolio
- The vaccine technology was acquired from ICAR-NIHSAD via Agrinnovate India